WEIGHT & METABOLISM / PEPTIDE CARD

Tirzepatide

A dual GIP and GLP-1 receptor agonist used in FDA-approved medicines for defined metabolic indications.

PEPTIDE CARDTirzepatide

Reviewed
August 7, 2026

Human evidence

5/5 · Large clinical program

U.S. FDAIndication-specific approval

2026 WADANot specifically named

Inspect 2 sources

On this page

WHAT THE EVIDENCE SAYS

Tirzepatide evidence summary.

Tirzepatide is an approved dual-receptor medicine with a mature human evidence base; it is not interchangeable with investigational retatrutide.

Entity type
Peptide analogSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

Approval and evidence attach to labeled products, not to every product marketed with the ingredient name.

01 / CLASSIFICATION

What is Tirzepatide?

Entity typePeptide analog

Research categoryWeight & Metabolism

Known namesTirzepatide

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Incretin receptor agonists Goal: Weight & Metabolism Goal: Visceral Fat Research

02 / EVIDENCE

Tirzepatide human and preclinical evidence.

HUMAN

5/5 · Large clinical program

Randomized trials and approved labeling support defined metabolic and sleep-apnea indications.

PRECLINICAL

4/5 · Well characterized

Dual GIP/GLP-1 pharmacology is well characterized; approved-use evidence is clinical.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

Tirzepatide FDA and sport status.

U.S. FDAFDA approved in specific branded products and indications; compounded products are not FDA approved.

2026 WADANot specifically named in the 2026 List; athletes should still verify product ingredients.

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is Tirzepatide being studied for?

01Type 2 diabetes

02Chronic weight management

03Obstructive sleep apnea

04Cardiometabolic outcomes

05 / COMPARISONS

Compare Tirzepatide.

Retatrutide vs TirzepatideAn investigational triple agonist compared with an approved dual agonist.Tirzepatide vs SemaglutideTwo approved metabolic medicines compared without flattening product labels or trial populations.Tesamorelin vs TirzepatideIndication-specific HIV-lipodystrophy evidence compared with dual-incretin metabolic evidence.AOD-9604 vs TirzepatideAn unapproved growth-hormone fragment compared with an approved dual-incretin medicine.

06 / LATEST & DEFINING SOURCES

Tirzepatide primary and official sources.

FDA / 2026Zepbound prescribing information

U.S. FDA

FDA / 2024FDA approves first medication for obstructive sleep apnea

U.S. FDA

07 / QUESTIONS

Questions about Tirzepatide.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for Tirzepatide?

Tirzepatide is an approved dual-receptor medicine with a mature human evidence base; it is not interchangeable with investigational retatrutide.

ResearchWhat is Tirzepatide being studied for?

Current source-backed research areas include Type 2 diabetes, Chronic weight management, Obstructive sleep apnea, Cardiometabolic outcomes. These areas describe investigation, not established personal benefit.

FDA statusIs Tirzepatide FDA approved?

Current U.S. status for Tirzepatide: FDA approved in specific branded products and indications; compounded products are not FDA approved.

Sport statusIs Tirzepatide prohibited in sport?

Current sport-status snapshot for Tirzepatide: Not specifically named in the 2026 List; athletes should still verify product ingredients.

Evidence limitsWhat are the main evidence limits for Tirzepatide?

Approval and evidence attach to labeled products, not to every product marketed with the ingredient name.